School of Health and Biomedical Sciences, RMIT University, Melbourne, Victoria, Australia.
Division of Health Sciences, University of South Australia, Adelaide, South Australia, Australia.
Diabetes Obes Metab. 2020 Jan;22(1):51-58. doi: 10.1111/dom.13864. Epub 2019 Sep 30.
To determine the effects of the dipeptidyl peptidase-4 inhibitor, sitagliptin, on gastric emptying (GE) of a high-carbohydrate meal and associated glycaemic and blood pressure (BP) responses in type 2 diabetes mellitus (T2DM).
Fourteen patients with T2DM (nine men, five women; age 67.8 ± 1.5 years; body mass index 31.2 ± 0.9 kg/m ; T2DM duration: 4.2 ± 0.9 years; glycated haemoglobin: 46 ± 1.8 mmol/mol [6.4% ± 0.2%]), managed by diet and/or metformin, underwent concurrent measurements of GE, BP and plasma glucose for 240 minutes after ingestion of a radiolabelled mashed potato meal after receiving sitagliptin (100 mg) or placebo in randomized, double-blind, crossover fashion on 2 consecutive days.
Sitagliptin reduced postprandial plasma glucose (P < .005) without affecting GE (P = .88). The magnitude of the glucose-lowering effect (change in incremental area under the curve from placebo to sitagliptin) was related to GE (kcal/min) on placebo (r = 0.68, P = .008) There was a comparable fall in systolic BP (P = .80) following the meal, with no difference between the 2 days.
In T2DM, while sitagliptin has no effect on either GE or postprandial BP, its ability to lower postprandial glucose are dependent on the basal rate of GE.
确定二肽基肽酶-4 抑制剂西他列汀对 2 型糖尿病（T2DM）患者高碳水化合物餐胃排空（GE）的影响及其对血糖和血压（BP）的相关影响。
14 例 T2DM 患者（9 名男性，5 名女性；年龄 67.8±1.5 岁；体重指数 31.2±0.9 kg/m2；T2DM 病程：4.2±0.9 年；糖化血红蛋白：46±1.8 mmol/mol[6.4%±0.2%]），通过饮食和/或二甲双胍进行治疗，在连续 2 天内以随机、双盲、交叉的方式分别服用西他列汀（100mg）或安慰剂后，同时测量 240 分钟内的 GE、BP 和血浆葡萄糖。
西他列汀降低了餐后血糖（P<0.005），但不影响 GE（P=0.88）。与安慰剂相比，西他列汀的降糖效果（从安慰剂到西他列汀的增量曲线下面积的变化）与 GE（千卡/分钟）相关（r=0.68，P=0.008）。餐后收缩压（P=0.80）也有类似下降，2 天之间无差异。
在 T2DM 中，西他列汀对 GE 或餐后 BP 均无影响，但它降低餐后血糖的能力取决于基础 GE 率。
